Arbutus Biopharma (ABUS) Interest & Investment Income (2013 - 2026)

Arbutus Biopharma has reported Interest & Investment Income for 14 years, with the latest figure at $815000.0 in Q1 2026.

• Quarterly Interest & Investment Income fell 31.91% year-over-year to $815000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (down 40.9% YoY) and the FY2025 annual result came in at $4.1 million, down 38.22% from the prior year.
• Interest & Investment Income fell to $815000.0 in Q1 2026 per ABUS's latest filing, from $877000.0 in the prior quarter.
• Over five years, Interest & Investment Income peaked at $1.8 million in Q2 2024 and troughed at $159000.0 in Q1 2022.
• A 5-year average of $1.1 million and a median of $1.2 million in 2025 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2022 and 2025: Interest & Investment Income jumped 3043.33% in 2022, then slumped 45.51% in 2025.
• Over 5 years, Interest & Investment Income stood at $943000.0 in 2022, then soared by 55.36% to $1.5 million in 2023, then retreated by 0.07% to $1.5 million in 2024, then slumped by 40.1% to $877000.0 in 2025, then slipped by 7.07% to $815000.0 in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $815000.0, $877000.0, and $952000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.